Statistical design
GIST
To estimate the sample size, a single-stage phase II clinical trial based on exact (binomial) tests has been used. The main endpoint will be to assess DCR taking into account the historical control with imatinib in wild-type GIST. Therefore, in H0, p0 will be taken as 73% (0% CR + 23% PR + 50% SD) [